Prevention and sequential therapies combined with drugs for postmenopausal osteoporosis

doi:10.3969/j.issn.2095-4344.2338

Abstract

Abstract:

BACKGROUND: In postmenopausal women, a rapid increase in bone resorption due to decreased estrogen levels leads to an imbalance between bone resorption and bone formation, increasing the risk of osteoporosis and associated fractures. However, current clinical interventions are not sufficient to inhibit long-term bone loss

and increased risk of fracture. In recent years, it has become an inevitable trend to treat postmenopausal osteoporosis with timely and effective prevention and sequential combination of anti-osteoporosis drugs.

OBJECTIVE: To summarize the literature on the prevention of postmenopausal osteoporosis and the anti-osteoporosis drug therapy, and introduce the progress of the clinical preventive measures and the common anti-osteoporosis drug combination sequential treatment of postmenopausal osteoporosis.

METHODS: The author retrieved the relevant articles in CNKI, Wanfang and PubMed databases from January 2009 to December 2019 in January 2020. The search words were “postmenopausal osteoporosis, prevention, drug therapy, medication” in Chinese and English respectively. Finally, 41 articles were selected according to inclusion and exclusion criteria for analysis and discussion.

RESULTS AND CONCLUSION: (1) Postmenopausal women should receive the test of bone mineral density and osteoporosis was prevented by changes in diet and lifestyle to reduce the risk of fractures. (2) Compared with single drugs, combination with sequential therapies can be more effective in the treatment of postmenopausal osteoporosis, which has far-reaching significance for the treatment of postmenopausal osteoporosis.

Key words: bone, postmenopausal, osteoporosis, fracture, prevention, drugs

CLC Number:

Sun Guoping, Luo Xuanxiang, Pan Bin. Prevention and sequential therapies combined with drugs for postmenopausal osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2020, 24(33): 5385-5390.

Figures/Tables 2

References

[1] YAN G, HUANG Y, CAO H, et al. Association of breastfeeding and postmenopausal osteoporosis in Chinese women: a community-based retrospective study. BMC Womens Health. 2019;19(1):110.

[2] SHEN Y, GRAY DL, MARTINEZ DS. Combined pharmacologic therapy in postmenopausal osteoporosis. Endocrinol Metab Clin North Am. 2016;46(1):193-206.

[3] THOR U, LIS S, JENS B. Bone matrix levels of dickkopf and sclerostin are positively correlated with bone mass and strength in postmenopausal osteoporosis. Int J Mol Sci. 2019; 20(12):2896.

[4] TANG D, JU C, LIU Y, et al. Therapeutic effect of icariin combined with stem cells on postmenopausal osteoporosis in rats. J Bone Miner Metabol. 2018;36(2):180-188.

[5] LIU H, LI B. Prospect of combination and sequential therapies for postmenopausal osteoporosis. Curr Pharm Design. 2017; 23(41):6251-6255.

[6] CHAN DC, LEE YS, WU YJ, et al. A 12-year ecological study of hip fracture rates among older Taiwanese adults. Calcif Tissue Int. 2013;93(5):397-404.

[7] MILLER DP. Management of severe osteoporosis. Exp Opin Pharmacother. 2016: 14656566.

[8] HILIGSMANN ML, EVERS SM, BEN SEDRINE W, et al. A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis. Pharmacoeconomics. 2015; 33(3):205-224.

[9] MIGNOT MA, TAISNE N, LEGROUX I, et al. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporosis Int. 2017;28(12): 3431-3438.

[10] JACKSON RD, MYSIW WJ. Insights into the epidemiology of postmenopausal osteoporosis: the Women's Health Initiative. Semin Reprod Med. 2014;32(6):454-462.

[11] PRENTICE RL, PETTINGER MB, JACKSON RD, et al. Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporosis Int. 2013;24(2):567-580.

[12] VERBRUGGE FH, EVELIEN G, KOEN M, et al. Who should receive calcium and vitamin D supplementation? Age Ageing. 2012; (5): 5.

[13] 中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊疗指南(2017)[J].中国骨质疏松杂志,2019,25(3):281-309.

[14] BISCHOFF-FERRARI HA, WILLETT WC, ORAV EJ, et al. A Pooled Analysis of Vitamin D Dose Requirements for Fracture Prevention. Obstetr Gynecol Surv. 2013;367(1):40-49.

[15] 王建华.骨质疏松症治疗药物的分类与用药选择[J].中华老年骨科与康复电子杂志,2019,5(5):297-300.

[16] ROSEN CJ, ADAMS JS, BIKLE DD, et al. The nonskeletal effects of Vitamin D: an endocrine society scientific statement. End Rev. 2012;33(3):456-492.

[17] DIAB DL, WATTS NB. Diagnosis and treatment of osteoporosis in older adults. Endocrinol Metab Clin North Am. 2013;42(2):305-317.

[18] US PREVENTIVE SERVICES TASK FORCE, CURRY SJ, KRIST AH, et al. Screening for osteoporosis to prevent fractures: us preventive services task force recommendation statement. JAMA. 2018;319(24):2521-2531.

[19] BONNICK SL, HARRIS ST, KENDLER DL, et al. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25-54.

[20] EVANS RK, NEGUS CH, CENTI AJ, et al. Peripheral QCT sector analysis reveals early exercise-induced increases in tibial bone mineral density. J Musculoskel Neur Int. 2012; 12(3):155-164.

[21] LIU GF, WANG ZQ, LIU L, et al. A network meta-analysis on the short-term efficacy and adverse events of different anti-osteoporosis drugs for the treatment of postmenopausal osteoporosis. J Cell Biochem.2018; 119(6):4469-4481.

[22] HSIAO FY, HSU WW. Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study. Jpn J Clin Oncol. 2017;47(10):935-941.

[23] BEAUDOIN C, JEAN S, BESSETTE L, et al. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos Int. 2016; 27(9): 2835-2844.

[24] MA YL, MARIN F, STEPAN J, et al. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis. Bone. 2011;48(5):972-978.

[25] LI X, OMINSKY MS, WARMINGTON KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-588.

[26] APPELMAN-DIJKSTRA NM, PAPAPOULOS SE. Sclerostin inhibition in the management of osteoporosis. Calcif Tissue Int. 2016;98(4):370-380.

[27] BLACK DM, REID IR, CAULEY JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934-944.

[28] GENNARI L, ROTATORI S, BIANCIARDI S, et al. Treatment needs and current options for postmenopausal osteoporosis. Exp Opin Pharmacother. 2016;17(8):1141-1152.

[29] TSAI JN, UIHLEIN AV, HANG L, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomised trial. Lancet. 2013; 382(9886):50-56.

[30] TSAI J, UIHLEIN A, BURNETT-BOWIE S, et al. Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab.2016:20161160.

[31] LEDER BZ, TSAI JN, UIHLEIN AV, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet (London, England). 2015; 386(9999): 1147-1155.

[32] LEDER BZ, TSAI JN, NEER RM, et al. Response to therapy with teriparatide, denosumab, or both in postmenopausal women in the DATA (denosumab and teriparatide administration) study randomized controlled trial. J Clin Densitom. 2016;19(3):346-351.

[33] FINKELSTEIN JS, WYLAND JJ, HANG L, et al. Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1838-1845.

[34] EASTELL R, NICKELSEN T, MARIN F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009; 24(4):726-736.

[35] MUSCHITZ C, KOCIJAN R, FAHRLEITNE-PAMMER A, et al. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density the CONFORS study. J Bone Miner Res. 2014;29(8):1777-1785.

[36] MCCLUNG MR, BROWN JP, DIEZ-PEREZ A, et al. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res. 2018;33(8): 1397-1406.

[37] ANASTASILAKIS AD, POLYZOS SA, EFSTATHIADOU ZA, et al. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers. Metabolism. 2015;64(10): 1291-1297.

[38] ANASTASILAKIS AD, POLYZOS SA, GKIOMISI A, et al. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporosis Int. 2015; 26(10): 2521-2527.

[39] LIN J, ZHU J, WANG Y, et al. Chinese single herbs and active ingredients for postmenopausal osteoporosis: From preclinical evidence to action mechanism. Biosci Trends. 2017;11(5): 496-506.

[40] KOMM BS, MORGENSTERN D, YAMAMOTO LA, et al. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women. Exp Rev Clini Pharmacol. 2015;8(6):1-16.

[41] MANDEMA JW, ZHENG J, LIBANATI C, et al. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response–based meta-analysis. J Clin Endocrinol Metab. 2014;99(10):3746-3755.